{"data":{"id":"us-il/215-ilcs-200-77","jurisdiction":"us-il","citation":"215 ILCS 200/77","heading":"Prior authorization for drug therapies for hereditary bleeding disorders.","body":"Notwithstanding any other provision of law, a health insurance issuer or a contracted utilization review organization may not require a prior authorization for drug therapies approved by the U.S. Food and Drug Administration for the treatment of hereditary bleeding disorders more frequently than every 6 months or the length of time the prescription for that dosage remains valid, whichever period is shorter.","path":["CHAPTER 215 INSURANCE","Prior Authorization Reform Act."],"source_url":"https://www.ilga.gov/legislation/ILCS/details?ActID=4201\u0026ChapterID=22\u0026ChapAct=FullText\u0026Print=True","current_through":"at least Public Act 104-790","vintage":"","retrieved_at":"2026-09-15T04:46:30Z","sha256":"c7b3e9d19946ce6c0f8f220c92244d816077c316db330d20951a9229615a5b94","source_id":"us-il","stale":false,"prev":"us-il/215-ilcs-200-75","next":"us-il/215-ilcs-200-80"},"notice":"GroundRules: Original legal text. Not legal advice."}